Agency Forms Undergoing Paperwork Reduction Act Review, 2615-2616 [2024-00651]
Download as PDF
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
accessdata.fda.gov/drugsatfda_docs/
nda/2012/125409Orig1s000PharmR.pdf
NIOSH [2016]. NIOSH list of
antineoplastic and other hazardous drugs
in healthcare settings, 2016. By Connor
TH, MacKenzie BA, DeBord DG, Trout
DB, O’Callaghan JP. Cincinnati, OH: U.S.
Department of Health and Human
Services, Centers for Disease Control and
Prevention, National Institute for
Occupational Safety and Health, DHHS
(NIOSH) Publication Number 2016–161.
https://www.cdc.gov/niosh/docs/2016161/ NIOSH [2023]. Procedures for
developing the NIOSH list of hazardous
drugs in healthcare settings. By
Whittaker C, Ovesen JL, MacKenzie BA,
Hartley T, Berry KA, Piacentino J.
Cincinnati, OH: U.S. Department of
Health and Human Services, Centers for
Disease Control and Prevention, National
Institute for Occupational Safety and
Health, DHHS (NIOSH) Publication No.
2023–129. https://www.cdc.gov/niosh/
docs/2023-129/.
3. Is a needlestick injury the only
reasonable route of exposure for
healthcare workers? Please explain.
4. Are the assumptions about the
amount of exposure to pertuzumab in a
healthcare setting reasonable? Please
explain.
5. Is the determination that the
amount of exposure to pertuzumab in a
healthcare setting does not constitute a
hazard for healthcare workers
reasonably supported by the available
scientific information? Please explain.
6. What alternatives could be
considered to this approach for
monoclonal antibodies to characterize
the potential hazard to workers?
ddrumheller on DSK120RN23PROD with NOTICES1
Public and Peer Review Charge for the
Reevaluation of Liraglutide on the
NIOSH List of Hazardous Drugs
The manufacturer’s request to
reevaluate the inclusion of liraglutide
on the NIOSH List proposed that it does
not present a potential hazard to
healthcare worker exposures because
the properties of the drug limit the
potential for exposure and therefore
adverse health effects from that
exposure. To reevaluate this drug,
NIOSH reviewed data regarding the
hazards and potential for systemic
exposure to liraglutide. Based on this
reevaluation NIOSH determined that
liraglutide does not meet the NIOSH
definition of a hazardous drug and
recommends that it be removed from the
List. Please review the NIOSH
reevaluation of liraglutide and consider
the following questions.
1. Are the evaluated health effects the
appropriate health effects to evaluate? If
not, what other health effect(s) should
be evaluated and why?
2. Are the assumptions about the
potential exposures to liraglutide in a
healthcare setting reasonable? Please
explain.
3. Is the determination that the
amount of exposure to liraglutide in a
healthcare setting does not constitute a
hazard for healthcare workers
reasonably supported by the available
scientific information? Please explain.
4. What alternative approaches could
be considered to characterize the
potential hazard to workers from
peptide-based drugs?
5. Is there any additional information
that NIOSH should consider in its
reevaluation of liraglutide?
References
FDA [2009]. Liraglutide Pharmacology
Review. Retrieved from https://www.
accessdata.fda.gov/scripts/cder/daf/.
FDA [2012]. US Food and Drug
Administration Pharmacology Review of
Perjeta. Retrieved from https://www.
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
John J. Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2024–00693 Filed 1–12–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–0576]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Possession,
Use, and Transfer of Select Agents and
Toxins (42 CFR part 73)’’ to the Office
of Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on August
15, 2023, to obtain comments from the
public and affected agencies. CDC did
not receive any comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
The CDC will accept all comments for
this proposed information collection
project. The OMB is particularly
interested in comments that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
2615
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Possession, Use, and Transfer of Select
Agents and Toxins (OMB Control No.
0920–0576, Exp. 1/31/2024)—
Revision—Office of Readiness and
Response (ORR), Centers for Disease
Control and Prevention (CDC)
Background and Brief Description
Subtitle A of the Public Health
Security and Bioterrorism Preparedness
and Response Act of 2002, (42 U.S.C.
262a), requires the United States
Department of Health and Human
Services (HHS) to regulate the
possession, use, and transfer of
biological agents or toxins that have the
potential to pose a severe threat to
public health and safety (select agents
and toxins). Subtitle B of the Public
Health Security and Bioterrorism
Preparedness and Response Act of 2002
(which may be cited as the Agricultural
Bioterrorism Protection Act of 2002), (7
U.S.C. 8401), requires the United States
Department of Agriculture (USDA) to
regulate the possession, use, and
transfer of biological agents or toxins
E:\FR\FM\16JAN1.SGM
16JAN1
2616
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
that have the potential to pose a severe
threat to animal or plant health, or
animal or plant products (select agents
and toxins). Accordingly, HHS and
USDA have promulgated regulations
requiring individuals or entities that
possess, use, or transfer select agents
and toxins to register with the Centers
for Disease Control and Prevention
(CDC) or the Animal and Plant Health
Inspection Service (APHIS). See 42 CFR
part 73, 7 CFR part 331, and 9 CFR part
121 (the select agent regulations). The
Federal Select Agent Program (FSAP) is
the collaboration of the CDC, Division of
Regulatory Science and Compliance
(DRSC) and the APHIS Division of
Agricultural Select Agents and Toxins
(DASAT) to administer the select agent
regulations in a manner to minimize the
administrative burden on persons
subject to the select agent regulations.
Accordingly, CDC and APHIS have
adopted an identical system to collect
information for the possession, use, and
transfer of select agents and toxins.
CDC is requesting OMB approval to
continue to collect information under
the select agent regulations through the
use of five forms: (1) Application for
Registration for Possession. Use, and
Transfer of Select Agents and Toxins
(APHIS/CDC Form 1); (2) Request to
Transfer Select Agents or Toxins
(APHIS/CDC Form 2); (3) Incident
Notification and Reporting (Theft, Loss,
or Release) (APHIS/CDC Form 3); (4)
Reporting the Identification of a Select
Agent or Toxin (APHIS/CDC Form 4);
and 5) Request for Exemption of Select
Agents and Toxins for an Investigational
Product (APHIS/CDC Form 5).
An entity may amend its registration
(Section 7(h)(1)) if any changes occur to
the information previously submitted to
FSAP. When applying for an
amendment to a certificate of
registration, an entity would complete
the relevant portion of the application
package (APHIS/CDC Form 1).
Besides the forms listed above, there
is no standard form for the following
information:
1. An individual or entity may request
an exclusion from the requirements of
the select agent regulations of an
attenuated strain of a select agent or a
select toxin modified to be less potent
or toxic. (Section 3(e) and 4(e)).
2. Annual inspections that are
conducted by the entity must be
documented. (Section 9(a)(6)).
3. An individual’s security risk
assessment may be expedited upon
written request by a Responsible Official
and a showing of good cause. (Section
10(f)).
4. An individual or entity may request
approval to perform a ‘‘restricted
experiment’’ (Section 13).
5. An individual or entity must
develop and implement a written
security plan, biosafety plan, and
incident response plan (Sections 11(a),
12(a), and 14(a)).
6. The Responsible Official must
ensure a record of the training for each
individual with access to select agents
and toxins and each escorted individual
is maintained (Section 15(d)).
7. An individual or entity may appeal
a denial, revocation, or suspension of
registration. (Section 20(a)).
8. An individual may appeal a denial,
limitation, or revocation of access
approval. (Section 20(b)).
The currently approved annualized
burden is 4467. CDC requests OMB
approval for an estimated 3504 annual
burden hours. The total estimated
annualized burden for all data
collection was calculated using the 2021
Annual Report of the FSAP available at
https://www.selectagents.gov/resources/
publications/annualreport/2021.htm.
Burden has been reduced due to a
decrease in the number of respondents.
Information will be collected through
the FSAP IT system, email, and hard
copy mail from respondents. Upon OMB
approval, CDC will begin use of the
revised forms in January 2024 through
January 2027. There is no cost to the
respondents other than their time.
ddrumheller on DSK120RN23PROD with NOTICES1
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Section
Form name
Sections 3 & 4 .........
Sections 5 & 6 .........
Sections 5 & 6 .........
Section 7 .................
Section 7 .................
Section 9 .................
Section 10 ...............
Section 11 ...............
Section 12 ...............
Section 13 ...............
Section 14 ...............
Section 15 ...............
Section 16 ...............
Section 17 ...............
Section 19 ...............
Section 20 ...............
Request for Exclusions ..........................................................................
Form 4—Report of Identification of a Select Agent or Toxin ................
Form 5—Request of Exemption ............................................................
Form 1—Application for Registration ....................................................
Form 1 Sec 6A—Amendment to a Certificate of Registration ..............
Documentation of self-inspection ..........................................................
Request for Expedited Review ..............................................................
Security Plan ..........................................................................................
Biosafety Plan ........................................................................................
Request Regarding a Restricted Experiment ........................................
Incident Response Plan .........................................................................
Training ..................................................................................................
Form 2—Request to Transfer Select Agents and Toxins .....................
Records ..................................................................................................
Form 3—Notification of Theft, Loss, or Release ...................................
Administrative Review ...........................................................................
1
917
1
5
144
233
1
233
233
3
233
233
229
233
185
22
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–00651 Filed 1–12–24; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
PO 00000
Frm 00035
Fmt 4703
Sfmt 9990
E:\FR\FM\16JAN1.SGM
16JAN1
Number of
responses per
respondent
1
1
1
1
5
1
1
1
1
1
1
1
1
1
1
1
Average
burden per
response
(in hours)
1
1
1
5
1
1
30/60
1
1
2
1
1
1.5
30/60
1
1
Agencies
[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2615-2616]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00651]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-24-0576]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Possession, Use, and Transfer of Select
Agents and Toxins (42 CFR part 73)'' to the Office of Management and
Budget (OMB) for review and approval. CDC previously published a
``Proposed Data Collection Submitted for Public Comment and
Recommendations'' notice on August 15, 2023, to obtain comments from
the public and affected agencies. CDC did not receive any comments
related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
The CDC will accept all comments for this proposed information
collection project. The OMB is particularly interested in comments
that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Possession, Use, and Transfer of Select Agents and Toxins (OMB Control
No. 0920-0576, Exp. 1/31/2024)--Revision--Office of Readiness and
Response (ORR), Centers for Disease Control and Prevention (CDC)
Background and Brief Description
Subtitle A of the Public Health Security and Bioterrorism
Preparedness and Response Act of 2002, (42 U.S.C. 262a), requires the
United States Department of Health and Human Services (HHS) to regulate
the possession, use, and transfer of biological agents or toxins that
have the potential to pose a severe threat to public health and safety
(select agents and toxins). Subtitle B of the Public Health Security
and Bioterrorism Preparedness and Response Act of 2002 (which may be
cited as the Agricultural Bioterrorism Protection Act of 2002), (7
U.S.C. 8401), requires the United States Department of Agriculture
(USDA) to regulate the possession, use, and transfer of biological
agents or toxins
[[Page 2616]]
that have the potential to pose a severe threat to animal or plant
health, or animal or plant products (select agents and toxins).
Accordingly, HHS and USDA have promulgated regulations requiring
individuals or entities that possess, use, or transfer select agents
and toxins to register with the Centers for Disease Control and
Prevention (CDC) or the Animal and Plant Health Inspection Service
(APHIS). See 42 CFR part 73, 7 CFR part 331, and 9 CFR part 121 (the
select agent regulations). The Federal Select Agent Program (FSAP) is
the collaboration of the CDC, Division of Regulatory Science and
Compliance (DRSC) and the APHIS Division of Agricultural Select Agents
and Toxins (DASAT) to administer the select agent regulations in a
manner to minimize the administrative burden on persons subject to the
select agent regulations. Accordingly, CDC and APHIS have adopted an
identical system to collect information for the possession, use, and
transfer of select agents and toxins.
CDC is requesting OMB approval to continue to collect information
under the select agent regulations through the use of five forms: (1)
Application for Registration for Possession. Use, and Transfer of
Select Agents and Toxins (APHIS/CDC Form 1); (2) Request to Transfer
Select Agents or Toxins (APHIS/CDC Form 2); (3) Incident Notification
and Reporting (Theft, Loss, or Release) (APHIS/CDC Form 3); (4)
Reporting the Identification of a Select Agent or Toxin (APHIS/CDC Form
4); and 5) Request for Exemption of Select Agents and Toxins for an
Investigational Product (APHIS/CDC Form 5).
An entity may amend its registration (Section 7(h)(1)) if any
changes occur to the information previously submitted to FSAP. When
applying for an amendment to a certificate of registration, an entity
would complete the relevant portion of the application package (APHIS/
CDC Form 1).
Besides the forms listed above, there is no standard form for the
following information:
1. An individual or entity may request an exclusion from the
requirements of the select agent regulations of an attenuated strain of
a select agent or a select toxin modified to be less potent or toxic.
(Section 3(e) and 4(e)).
2. Annual inspections that are conducted by the entity must be
documented. (Section 9(a)(6)).
3. An individual's security risk assessment may be expedited upon
written request by a Responsible Official and a showing of good cause.
(Section 10(f)).
4. An individual or entity may request approval to perform a
``restricted experiment'' (Section 13).
5. An individual or entity must develop and implement a written
security plan, biosafety plan, and incident response plan (Sections
11(a), 12(a), and 14(a)).
6. The Responsible Official must ensure a record of the training
for each individual with access to select agents and toxins and each
escorted individual is maintained (Section 15(d)).
7. An individual or entity may appeal a denial, revocation, or
suspension of registration. (Section 20(a)).
8. An individual may appeal a denial, limitation, or revocation of
access approval. (Section 20(b)).
The currently approved annualized burden is 4467. CDC requests OMB
approval for an estimated 3504 annual burden hours. The total estimated
annualized burden for all data collection was calculated using the 2021
Annual Report of the FSAP available at https://www.selectagents.gov/resources/publications/annualreport/2021.htm. Burden has been reduced
due to a decrease in the number of respondents. Information will be
collected through the FSAP IT system, email, and hard copy mail from
respondents. Upon OMB approval, CDC will begin use of the revised forms
in January 2024 through January 2027. There is no cost to the
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Section Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Sections 3 & 4..................... Request for Exclusions..... 1 1 1
Sections 5 & 6..................... Form 4--Report of 917 1 1
Identification of a Select
Agent or Toxin.
Sections 5 & 6..................... Form 5--Request of 1 1 1
Exemption.
Section 7.......................... Form 1--Application for 5 1 5
Registration.
Section 7.......................... Form 1 Sec 6A--Amendment to 144 5 1
a Certificate of
Registration.
Section 9.......................... Documentation of self- 233 1 1
inspection.
Section 10......................... Request for Expedited 1 1 30/60
Review.
Section 11......................... Security Plan.............. 233 1 1
Section 12......................... Biosafety Plan............. 233 1 1
Section 13......................... Request Regarding a 3 1 2
Restricted Experiment.
Section 14......................... Incident Response Plan..... 233 1 1
Section 15......................... Training................... 233 1 1
Section 16......................... Form 2--Request to Transfer 229 1 1.5
Select Agents and Toxins.
Section 17......................... Records.................... 233 1 30/60
Section 19......................... Form 3--Notification of 185 1 1
Theft, Loss, or Release.
Section 20......................... Administrative Review...... 22 1 1
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-00651 Filed 1-12-24; 8:45 am]
BILLING CODE 4163-18-P